Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325754 | 0.89 | CYP1A2 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL7994439 | 0.88 | CYP1A2 (0.30) | — | |
| SCHEMBL7479466 | 0.86 | — | — | |
| SCHEMBL2141114 | 0.86 | MAPK1 (0.38) | ALDH1A1ALOX15MAPK1KDM4EHSD17B10 | |
| SCHEMBL2136195 | 0.86 | MAPK1 (0.38) | ALDH1A1ALOX15MAPK1KDM4EHSD17B10 | |
| SCHEMBL7992356 | 0.86 | CYP1A2 (0.33) | — | |
| SCHEMBL7992364 | 0.86 | CYP1A2 (0.33) | — | |
| SCHEMBL2138060 | 0.84 | MAPK1 (0.37) | ALDH1A1ALOX15MAPK1KDM4EHSD17B10 | |
| SCHEMBL11075927 | 0.84 | MAPK1 (0.37) | ALDH1A1ALOX15MAPK1KDM4EHSD17B10 | |
| SCHEMBL7991276 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3960906-A | INSECTICIDES | SANDOZ LTD. (CH) | 1976-06-01 | — | — | US | claimed |
| WO-2009145357-A1 | IN 1-POSITION DURCH EINEN RING SUBSTITUIERTE BENZO [1, 4] DIAZEPINE ZUR VERWENDUNGS ALS ANTIDEPRESSIVA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | WO | disclosed |
| US-20080255121-A1 | Combination Drug for Treating Autoimmune Disease | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| CN-101052420-A | Combination drug for treating autoimmune diseases | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-10 | — | — | CN | disclosed |
| EP-1815867-A1 | COMBINATION DRUG FOR TREATING AUTOIMMUNE DISEASE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-0979226-B1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1122253-B1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-08-17 | — | — | EP | disclosed |
| CN-1202095-C | Heteroaromatic ring compounds | SUMITOMO PHARMA (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| EP-1122253-A1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-6100260-A | ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION | SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6063782-A | Pyrrolopyridazine derivatives | SANKYO COMPANY, LIMITED (JP) | 2000-05-16 | — | — | US | disclosed |
| EP-0979226-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0626373-B1 | Quinazolinone derivatives | SUMITOMO PHARMA (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998047880-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-10-29 | — | — | WO | disclosed |
| CN-1143964-A | Pyrrolopyridazine derivative | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
| EP-0742218-A1 | PYRROLOPYRIDAZINE DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5556860-A | ANTIISCHEMIC AGENTS, BRAIN DISORDERS AND BLOOD METAL CONCENTRATIONS AND KIDNEY DISEASE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0626373-A1 | Quinazolinone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255121-A1 | Combination Drug for Treating Autoimmune Disease | CAMK2D, CAMK2G, CAMK2B | ALDH1A1 3999/4885ALOX15 3680/4885MAPK1 280/4885 |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | ALDH1A1 37/4885ALOX15 1525/4885MAPK1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.